Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Leaky Scanning

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...

Conjugated Proteins

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sequence basis for selectivity of ephrin-B2 ligand for Eph receptors and pathogenic henipavirus G glycoproteins.

Journal of virology·2023

Same author

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.

Communications biology·2023

Same author

Xeno interactions between MHC-I proteins and molecular chaperones enable ligand exchange on a broad repertoire of HLA allotypes.

Science advances·2023

Same author

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.

EMBO molecular medicine·2022

Same author

TAPBPR employs a ligand-independent docking mechanism to chaperone MR1 molecules.

Nature chemical biology·2022

Same author

A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.

Proceedings of the National Academy of Sciences of the United States of America·2022

Search research articles

Related Experiment Video

Updated: Nov 6, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

ACE2-based decoy receptors for SARS coronavirus 2.

Wenyang Jing¹, Erik Procko^1,2

¹Center for Biophysics and Quantitative Biology, University of Illinois, Urbana, Illinois, USA.

|May 11, 2021

Summary

Engineered soluble angiotensin-converting enzyme 2 (ACE2) decoys show promise as broad-acting therapeutics against SARS-associated coronaviruses. These ACE2 derivatives offer dual mechanisms of action for treating COVID-19 and preventing related injuries.

Keywords:

ACE2 COVID-19 SARS coronavirus 2 avidity decoy receptor protein engineering

More Related Videos

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Related Experiment Videos

Last Updated: Nov 6, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Area of Science:

Virology
Immunology
Biochemistry

Background:

SARS-CoV-2 utilizes spike proteins to bind the ACE2 receptor for cell entry.
Monoclonal antibodies are emerging therapies but have limitations in efficacy and viral escape.
Soluble ACE2 decoys present an alternative strategy for broad coronavirus neutralization.

Purpose of the Study:

To summarize advancements in engineering soluble ACE2 variants with enhanced affinity and potency.
To explore strategies for improving ACE2 decoy efficacy, including increased valency and pharmacokinetic optimization.
To highlight the dual mechanism of action of ACE2 derivatives in combating viral infection and host injury.

Main Methods:

Engineering higher affinity soluble ACE2 variants.
Increasing decoy valency for enhanced spike protein binding.
Developing IgG fusions to improve pharmacokinetics.

Main Results:

Engineered soluble ACE2 variants demonstrate potency rivaling affinity-matured antibodies.
Increased valency and IgG fusions enhance ACE2 decoy interactions with viral spikes.
ACE2's intrinsic enzymatic activity offers a dual mechanism against viral infection and associated organ damage.

Conclusions:

Soluble ACE2 derivatives represent a promising next-generation therapeutic for SARS-CoV-2 and future coronavirus outbreaks.
These decoys offer broad-spectrum neutralization with a lower potential for viral escape compared to antibodies.
The dual action of viral blocking and enzymatic activity provides a unique therapeutic advantage.